KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to -$1.0 million.

  • Charles River Laboratories International's Gains from Investment Securities rose 6755.07% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.7 million, marking a year-over-year decrease of 821055.72%. This contributed to the annual value of -$33.3 million for FY2024, which is 154947.69% down from last year.
  • As of Q3 2025, Charles River Laboratories International's Gains from Investment Securities stood at -$1.0 million, which was up 6755.07% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, Charles River Laboratories International's Gains from Investment Securities peaked at $15.5 million during Q4 2022, and registered a low of -$24.4 million during Q4 2024.
  • In the last 5 years, Charles River Laboratories International's Gains from Investment Securities had a median value of -$3.2 million in 2024 and averaged -$4.5 million.
  • Examining YoY changes over the last 5 years, Charles River Laboratories International's Gains from Investment Securities showed a top increase of 16455.33% in 2022 and a maximum decrease of 1572931.03% in 2022.
  • Over the past 5 years, Charles River Laboratories International's Gains from Investment Securities (Quarter) stood at -$23.9 million in 2021, then surged by 164.55% to $15.5 million in 2022, then tumbled by 40.21% to $9.2 million in 2023, then tumbled by 363.51% to -$24.4 million in 2024, then skyrocketed by 95.73% to -$1.0 million in 2025.
  • Its Gains from Investment Securities was -$1.0 million in Q3 2025, compared to $1.5 million in Q2 2025 and -$3.7 million in Q1 2025.